Advanced Biomed entered into a Share Purchase Agreement to sell 100% of its Taiwan subsidiary for $490,000 to an unrelated third party. The unit includes the company’s biomedical R&D operations and the A+PerfusC integrated perfusion 3D cell culture platform. Closing is expected within three months, subject to customary conditions. Advanced Biomed will continue operating its remaining businesses, including AI-focused activities through Acellent Technologies (Hong Kong).
Agreement details:
- Agreement type: Share Purchase Agreement for sale of 100% of Taiwan Subsidiary
- Counterparty: Unrelated third party
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: N/A
- Reason: Refocus on AI operations and streamline portfolio
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.